臨牀透析 Vol.19 No.8(4)


特集名 透析医療におけるウーマン・ヘルス
題名 女性透析患者の骨代謝異常
発刊年月 2003年 07月
著者 衣笠 えり子 昭和大学横浜市北部病院内科
著者 伊藤 英利 昭和大学横浜市北部病院内科
著者 坂下 暁子 昭和大学横浜市北部病院内科
【 要旨 】 女性透析患者の骨代謝異常は,腎性骨異栄養症(ROD)にエストロゲン欠乏による骨量減少が加わり複雑な病態を呈する.問題は両者に起因する骨量減少による骨折リスクの増加であり,患者QOLや予後に大きく影響する.治療は現時点ではROD対策を優先して適切なCa,P,PTH濃度の管理を行い,定期的な骨密度測定による評価を行う.現時点では,ホルモン補充療法については副作用を勘案して慎重に対処すべきであり,またそのほかの骨粗頏。療薬の女性透析患者に対する有効性のエビデンスは確立されていない.骨量減少の危険因子の排除も重要で,とくに臥床状態を避けるための適度な運動は有用と考えられる.今後は,透析導入前からの骨代謝障害に対する介入治療も望まれる.
Theme Characteristic Problems in Managing Female Dialysis Patients
Title Abnormality of bone metabolism in hemodialyzed women
Author Eriko Kinugasa Department of Internal Medicine, Showa University, Northern Yokohama Hospital
Author Hidetoshi Ito Department of Internal Medicine, Showa University, Northern Yokohama Hospital
Author Akiko Sakashita Department of Internal Medicine, Showa University, Northern Yokohama Hospital
[ Summary ] Bone metabolism in female hemodialysis patients is complicated because of the coexistence of renal osteodystrophy (ROD) and metabolic bone disease originating from estrogen deficiency, both of which act to prevent loss of bone minerals. The most significant problem related to this condition is that there is increased risk of bone fractures with this abnormal bone metabolism, which influences the quality of life and the future prognosis for these patients. At the present time, the therapeutic approach mainly directs us in treatment of ROD, with such things as proper control of serum calcium, phosphorus and parathyroid hormone, along with activated vitamin D and calcium salts. The long term safety of hormone replacement therapy in women receiving hemodialysis is not certain at this time. The clinical usefulness of other therapeutic agents, which are generally used for treatment of osteoporosis, is not obvious in hemodialysis patients. The avoidance of risk factors related to osteoporosis, such as immobilization, malnutrition, smoking and alcohol, is also important to prevent further loss of bone minerals. Finally, this condition should be considered in relation to therapeutic intervention from the start of the pre-dialysis period.
戻る